Figure 1.
nhr-67 Is Required for Proper Gene Expression in Multiple Vulval Cell Types Lateral images of the developing vulva during the L4 (A-D and G-L) and the adult stage (E and F). (A-L) Nomarski (left), fluorescence (center), and overlaid (right). Expression of vulval cell fate markers in wild-type (A, C, E, G, I, and K) and
nhr-67 RNAi-treated animals (B, D, F, H, J, and L). In
nhr-67 RNAi-treated animals, the vulval morphology is abnormal compared to wild-type; namely, the migration of vulF cells is defective. (A) In wild-type animals, syIs55 [
ceh-2::YFP] expression is off in the 1 vulF cells (arrows). (B) syIs55 animals treated with
nhr-67 RNAi show ectopic
ceh-2 expression in the 1 vulF cells (arrow). (C) kuIs36 [
egl-26::GFP] expression is completely absent in the vulF cells (arrows). (D)
nhr-67 RNAi results in misexpression of
egl-26 in the vulF lineages (arrowheads). (E) Wild-type
zmp-1::GFP (syIs49) expression is observed in the vulA cells (arrows). (F) In contrast,
nhr-67 RNAi abolishes the vulA-specific expression (arrows) of
zmp-1. (G) guEx64 [
pax-2::GFP] is expressed exclusively in vulD cells (arrows) in wild-type animals. (H)
pax-2 expression in vulD is abolished in an
nhr-67 (RNAi) background (arrows). (I) Wild-type
egl-17::GFP (syIs59) expression is observed in the vulD cells (arrows). (J)
nhr-67 RNAi results in the loss of
egl-17 expression in the vulD cells (arrows). (K) In wild-type animals,
lin-3::GFP (syIs107) is expressed solely in vulF cells (arrows). (L)
lin-3 expression in vulF cells is eliminated when treated with
nhr-67 RNAi (arrows).